(Q35212506)

7 August 2017

1 reference

title

The use of alpha1-adrenoceptor antagonists in lower urinary tract symptoms: beyond benign prostatic hyperplasia (English)

1 reference

7 August 2017

J Curtis Nickel

1

1 reference

7 August 2017

language of work or name

English

0 references

publication date

1 September 2003

1 reference

7 August 2017

1 reference

7 August 2017

volume

62

1 reference

7 August 2017

issue

3 Suppl 1

1 reference

7 August 2017

page(s)

34-41

1 reference

High prevalence of benign prostatic hypertrophy in the community

7 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900472-2

7 January 2021

The prevalence of prostatism: a population-based survey of urinary symptoms

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900472-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900472-2

7 January 2021

The International Continence Society “Benign Prostatic Hyperplasia” Study: The Bothersomeness of Urinary Symptoms

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900472-2

7 January 2021

Introduction and Concluding Remarks

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900472-2

7 January 2021

Potential mechanisms of action of superselective alpha(1)-adrenoceptor antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900472-2

7 January 2021

Diagnosis and treatment of chronic abacterial prostatitis: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900472-2

7 January 2021

HOW COMMON IS PROSTATITIS? A NATIONAL SURVEY OF PHYSICIAN VISITS

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900472-2

7 January 2021

Diagnosis and treatment of prostatitis in Canada.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900472-2

7 January 2021

Prevalence of a Physician-Assigned Diagnosis of Prostatitis: The Olmsted County Study of Urinary Symptoms and Health Status Among Men

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900472-2

7 January 2021

Prevalence of prostatitis-like symptoms in a population based study using the National Institutes of Health chronic prostatitis symptom index

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900472-2

7 January 2021

Distinguishing chronic prostatitis and benign prostatic hyperplasia symptoms: results of a national survey of physician visits

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900472-2

7 January 2021

Prostatodynia--physiological characteristics and rational management with muscle relaxants

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900472-2

7 January 2021

Use of terazosin in prostatodynia and validation of a symptom score questionnaire

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900472-2

7 January 2021

Use of terazosine in patients with chronic pelvic pain syndrome and evaluation by prostatitis symptom score index

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900472-2

7 January 2021

Research guidelines for chronic prostatitis: consensus report from the first National Institutes of Health International Prostatitis Collaborative Network

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900472-2

7 January 2021

Design of a multicenter randomized clinical trial for chronic prostatitis/chronic pelvic pain syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900472-2

7 January 2021

Recent advances in the management of the neurogenic bladder

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900472-2

7 January 2021

Alpha-adrenoceptor antagonists in neurogenic lower urinary tract dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900472-2

7 January 2021

Effect of intravenous alfuzosin on urethral pressure in patients with neurogenic bladder dysfunction. DORALI Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900472-2

7 January 2021

Phenoxybenzamine in neurogenic bladder dysfunction. II. Clinical considerations.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900472-2

7 January 2021

The effect of urapidil on neurogenic bladder: a placebo controlled double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900472-2

7 January 2021

The effect of terazosin on bladder function in the spinal cord injured patient

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900472-2

7 January 2021

Neoadjuvant and adjuvant alpha-blockade improves early results of high-energy transurethral microwave thermotherapy for lower urinary tract symptoms of benign prostatic hyperplasia: a randomized, prospective clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900472-2

7 January 2021

Tamsulosin palliates radiation-induced urethritis in patients with prostate cancer: results of a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900472-2

7 January 2021

Temporal resolution of urinary morbidity following prostate brachytherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900472-2

7 January 2021

Natural history of prostatism: risk factors for acute urinary retention

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900472-2

7 January 2021

A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. The Veterans Affairs Cooperative Study Group on Transurethral Resection of the Prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900472-2

7 January 2021

The natural history of patients with benign prostatic hyperplasia as diagnosed by North American urologists

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900472-2

7 January 2021

Sustained-release alfuzosin and trial without catheter after acute urinary retention: a prospective, placebo-controlled.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900472-2

7 January 2021

Prevention of Post-Hysterectomy Urinary Retention by Alpha-Adrenergic Blocker

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900472-2

7 January 2021

Alpha-adrenergic blocker for posthernioplasty urinary retention. Prevention and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900472-2

7 January 2021

Prevention of prolonged voiding problems after unexpected postoperative urinary retention: comparison of phenoxybenzamine and carbachol

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900472-2

7 January 2021

Prevention of urinary retention after general surgery: a controlled trial of carbachol/diazepam versus alfusozine.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900472-2

7 January 2021

10.1016/S0090-4295(03)00472-2

Identifiers

DOI

1 reference

7 August 2017

1 reference